Target	Disease	Drug_index	Drug
CD80	juvenile idiopathic arthritis	1	abatacept [T-lymphocyte activation antigen CD80 inhibitor] (phase-IV)
CD80	psoriatic arthritis	1	abatacept [T-lymphocyte activation antigen CD80 inhibitor] (phase-IV)
CD80	rheumatoid arthritis	1	abatacept [T-lymphocyte activation antigen CD80 inhibitor] (phase-IV)
CD80	immune system disease	2	abatacept [T-lymphocyte activation antigen CD80 inhibitor] (phase-IV), belatacept [T-lymphocyte activation antigen CD80 inhibitor] (phase-IV)
CD86	juvenile idiopathic arthritis	3	abatacept [T-lymphocyte activation antigen CD86 inhibitor] (phase-IV)
CD86	psoriatic arthritis	3	abatacept [T-lymphocyte activation antigen CD86 inhibitor] (phase-IV)
CD86	rheumatoid arthritis	3	abatacept [T-lymphocyte activation antigen CD86 inhibitor] (phase-IV)
CD86	immune system disease	4	abatacept [T-lymphocyte activation antigen CD86 inhibitor] (phase-IV), belatacept [T-lymphocyte activation antigen CD86 inhibitor] (phase-IV)
JAK1	Eczema	5	abrocitinib [Tyrosine-protein kinase JAK1 inhibitor] (phase-IV)
JAK1	atopic eczema	5	abrocitinib [Tyrosine-protein kinase JAK1 inhibitor] (phase-IV)
TNF	arthritis	6	adalimumab [TNF-alpha inhibitor] (phase-IV)
TNF	ankylosing spondylitis	7	adalimumab [TNF-alpha inhibitor] (phase-IV), certolizumab pegol [TNF-alpha inhibitor] (phase-IV), etanercept [TNF-alpha inhibitor] (phase-IV), golimumab [TNF-alpha inhibitor] (phase-IV), infliximab [TNF-alpha inhibitor] (phase-IV)
TNF	immune system disease	7	adalimumab [TNF-alpha inhibitor] (phase-IV), certolizumab pegol [TNF-alpha inhibitor] (phase-IV), etanercept [TNF-alpha inhibitor] (phase-IV), golimumab [TNF-alpha inhibitor] (phase-IV), infliximab [TNF-alpha inhibitor] (phase-IV)
TNF	psoriatic arthritis	7	adalimumab [TNF-alpha inhibitor] (phase-IV), certolizumab pegol [TNF-alpha inhibitor] (phase-IV), etanercept [TNF-alpha inhibitor] (phase-IV), golimumab [TNF-alpha inhibitor] (phase-IV), infliximab [TNF-alpha inhibitor] (phase-IV)
TNF	rheumatoid arthritis	7	adalimumab [TNF-alpha inhibitor] (phase-IV), certolizumab pegol [TNF-alpha inhibitor] (phase-IV), etanercept [TNF-alpha inhibitor] (phase-IV), golimumab [TNF-alpha inhibitor] (phase-IV), infliximab [TNF-alpha inhibitor] (phase-IV)
TNF	psoriasis	8	adalimumab [TNF-alpha inhibitor] (phase-IV), etanercept [TNF-alpha inhibitor] (phase-IV), infliximab [TNF-alpha inhibitor] (phase-IV)
TNF	ulcerative colitis	9	adalimumab [TNF-alpha inhibitor] (phase-IV), golimumab [TNF-alpha inhibitor] (phase-IV), infliximab [TNF-alpha inhibitor] (phase-IV)
IL2RG	cutaneous melanoma	10	aldesleukin [Interleukin-2 receptor agonist] (phase-IV)
IL2RB	cutaneous melanoma	10	aldesleukin [Interleukin-2 receptor agonist] (phase-IV)
IL2RA	cutaneous melanoma	10	aldesleukin [Interleukin-2 receptor agonist] (phase-IV)
IL2RG	melanoma	10	aldesleukin [Interleukin-2 receptor agonist] (phase-IV)
IL2RB	melanoma	10	aldesleukin [Interleukin-2 receptor agonist] (phase-IV)
IL2RA	melanoma	10	aldesleukin [Interleukin-2 receptor agonist] (phase-IV)
IL2RG	metastatic melanoma	10	aldesleukin [Interleukin-2 receptor agonist] (phase-IV)
IL2RB	metastatic melanoma	10	aldesleukin [Interleukin-2 receptor agonist] (phase-IV)
IL2RA	metastatic melanoma	10	aldesleukin [Interleukin-2 receptor agonist] (phase-IV)
DPP4	type 2 diabetes mellitus	11	alogliptin benzoate [Dipeptidyl peptidase IV inhibitor] (phase-IV), linagliptin [Dipeptidyl peptidase IV inhibitor] (phase-IV), saxagliptin hydrochloride [Dipeptidyl peptidase IV inhibitor] (phase-IV), sitagliptin phosphate [Dipeptidyl peptidase IV inhibitor] (phase-IV)
IFNAR1	immune system disease	12	anifrolumab [Interferon-alpha/beta receptor alpha chain antagonist] (phase-IV)
IFNAR1	systemic lupus erythematosus	12	anifrolumab [Interferon-alpha/beta receptor alpha chain antagonist] (phase-IV)
JAK1	immune system disease	13	baricitinib [Tyrosine-protein kinase JAK1 inhibitor] (phase-IV), filgotinib [Tyrosine-protein kinase JAK1 inhibitor] (phase-IV), upadacitinib [Janus Kinase (JAK) inhibitor] (phase-IV)
JAK1	rheumatoid arthritis	14	baricitinib [Tyrosine-protein kinase JAK1 inhibitor] (phase-IV), tofacitinib citrate [Janus Kinase (JAK) inhibitor] (phase-IV), upadacitinib [Janus Kinase (JAK) inhibitor] (phase-IV)
JAK2	rheumatoid arthritis	15	baricitinib [Tyrosine-protein kinase JAK2 inhibitor] (phase-IV), tofacitinib citrate [Janus Kinase (JAK) inhibitor] (phase-IV), upadacitinib [Janus Kinase (JAK) inhibitor] (phase-IV)
JAK2	immune system disease	16	baricitinib [Tyrosine-protein kinase JAK2 inhibitor] (phase-IV), upadacitinib [Janus Kinase (JAK) inhibitor] (phase-IV)
IL2RG	immune system disease	17	basiliximab [Interleukin-2 receptor inhibitor] (phase-IV)
IL2RB	immune system disease	17	basiliximab [Interleukin-2 receptor inhibitor] (phase-IV)
IL2RA	immune system disease	17	basiliximab [Interleukin-2 receptor inhibitor] (phase-IV)
IL1B	CINCA syndrome	18	canakinumab [Interleukin-1 beta inhibitor] (phase-IV)
IL1B	familial Mediterranean fever	18	canakinumab [Interleukin-1 beta inhibitor] (phase-IV)
IL1B	juvenile idiopathic arthritis	18	canakinumab [Interleukin-1 beta inhibitor] (phase-IV)
IL1B	mevalonate kinase deficiency	18	canakinumab [Interleukin-1 beta inhibitor] (phase-IV)
IL1B	Muckle-Wells syndrome	19	canakinumab [Interleukin-1 beta inhibitor] (phase-IV), rilonacept [Interleukin-1 beta inhibitor] (phase-IV)
IL1B	cryopyrin-associated periodic syndrome	19	canakinumab [Interleukin-1 beta inhibitor] (phase-IV), rilonacept [Interleukin-1 beta inhibitor] (phase-IV)
IL1B	immune system disease	19	canakinumab [Interleukin-1 beta inhibitor] (phase-IV), rilonacept [Interleukin-1 beta inhibitor] (phase-IV)
TNF	inflammation	20	certolizumab pegol [TNF-alpha inhibitor] (phase-IV)
TNF	Crohn's disease	21	certolizumab pegol [TNF-alpha inhibitor] (phase-IV), infliximab [TNF-alpha inhibitor] (phase-IV)
IL2RG	Cutaneous T-cell lymphoma	22	denileukin diftitox [Interleukin-2 receptor binding agent] (phase-IV)
IL2RB	Cutaneous T-cell lymphoma	22	denileukin diftitox [Interleukin-2 receptor binding agent] (phase-IV)
IL2RA	Cutaneous T-cell lymphoma	22	denileukin diftitox [Interleukin-2 receptor binding agent] (phase-IV)
TNF	juvenile idiopathic arthritis	23	etanercept [TNF-alpha inhibitor] (phase-IV)
TNF	psoriasis vulgaris	23	etanercept [TNF-alpha inhibitor] (phase-IV)
TNF	spondylitis	24	etanercept [TNF-alpha inhibitor] (phase-IV), golimumab [TNF-alpha inhibitor] (phase-IV)
JAK2	primary myelofibrosis	25	fedratinib hydrochloride [Tyrosine-protein kinase JAK2 inhibitor] (phase-IV), pacritinib citrate [Tyrosine-protein kinase JAK2 inhibitor] (phase-IV), ruxolitinib phosphate [Tyrosine-protein kinase JAK2 inhibitor] (phase-IV)
JAK2	Myelofibrosis	26	fedratinib hydrochloride [Tyrosine-protein kinase JAK2 inhibitor] (phase-IV), ruxolitinib phosphate [Tyrosine-protein kinase JAK2 inhibitor] (phase-IV)
TLR7	malaria	27	hydroxychloroquine sulfate [Toll-like receptor 7 antagonist] (phase-IV)
TLR7	rheumatoid arthritis	27	hydroxychloroquine sulfate [Toll-like receptor 7 antagonist] (phase-IV)
TLR7	actinic keratosis	28	imiquimod [Toll-like receptor 7 agonist] (phase-IV)
TLR7	basal cell carcinoma	28	imiquimod [Toll-like receptor 7 agonist] (phase-IV)
TLR7	keratosis	28	imiquimod [Toll-like receptor 7 agonist] (phase-IV)
TLR7	skin basal cell carcinoma	28	imiquimod [Toll-like receptor 7 agonist] (phase-IV)
TLR7	viral disease	28	imiquimod [Toll-like receptor 7 agonist] (phase-IV)
IFNAR2	Kaposi's sarcoma	29	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR1	Kaposi's sarcoma	29	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR2	anogenital venereal wart	29	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR1	anogenital venereal wart	29	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR2	follicular lymphoma	29	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR1	follicular lymphoma	29	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR2	hairy cell leukemia	29	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR1	hairy cell leukemia	29	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR2	chronic hepatitis B virus infection	30	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV), peginterferon alfa-2a [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR1	chronic hepatitis B virus infection	30	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV), peginterferon alfa-2a [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR2	hepatitis B virus infection	30	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV), peginterferon alfa-2a [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR1	hepatitis B virus infection	30	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV), peginterferon alfa-2a [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR2	chronic hepatitis C virus infection	31	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV), peginterferon alfa-2a [Interferon alpha/beta receptor agonist] (phase-IV), peginterferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR1	chronic hepatitis C virus infection	31	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV), peginterferon alfa-2a [Interferon alpha/beta receptor agonist] (phase-IV), peginterferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR2	cutaneous melanoma	32	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV), peginterferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR1	cutaneous melanoma	32	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV), peginterferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR2	melanoma	32	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV), peginterferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR1	melanoma	32	interferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV), peginterferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR2	multiple sclerosis	33	interferon beta-1a [Interferon alpha/beta receptor agonist] (phase-IV), interferon beta-1b [Interferon alpha/beta receptor agonist] (phase-IV), peginterferon beta-1a [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR1	multiple sclerosis	33	interferon beta-1a [Interferon alpha/beta receptor agonist] (phase-IV), interferon beta-1b [Interferon alpha/beta receptor agonist] (phase-IV), peginterferon beta-1a [Interferon alpha/beta receptor agonist] (phase-IV)
DPP4	diabetes mellitus	34	linagliptin [Dipeptidyl peptidase IV inhibitor] (phase-IV), vildagliptin [Dipeptidyl peptidase IV inhibitor] (phase-IV)
CCR5	HIV infection	35	maraviroc [C-C chemokine receptor type 5 antagonist] (phase-IV)
CCR5	HIV-1 infection	35	maraviroc [C-C chemokine receptor type 5 antagonist] (phase-IV)
CCR5	immunodeficiency disease	35	maraviroc [C-C chemokine receptor type 5 antagonist] (phase-IV)
CCR5	viral disease	35	maraviroc [C-C chemokine receptor type 5 antagonist] (phase-IV)
JAK2	polycythemia vera	36	pacritinib citrate [Tyrosine-protein kinase JAK2 inhibitor] (phase-IV), ruxolitinib phosphate [Tyrosine-protein kinase JAK2 inhibitor] (phase-IV)
IFNAR2	metastatic melanoma	37	peginterferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV)
IFNAR1	metastatic melanoma	37	peginterferon alfa-2b [Interferon alpha/beta receptor agonist] (phase-IV)
IL1B	Familial cold urticaria	38	rilonacept [Interleukin-1 beta inhibitor] (phase-IV)
IL1B	pericarditis	38	rilonacept [Interleukin-1 beta inhibitor] (phase-IV)
IFNAR2	polycythemia vera	39	ropeginterferon alfa-2b [Interferon alpha/beta receptor positive modulator] (phase-IV)
IFNAR1	polycythemia vera	39	ropeginterferon alfa-2b [Interferon alpha/beta receptor positive modulator] (phase-IV)
JAK1	Myelofibrosis	40	ruxolitinib phosphate [Tyrosine-protein kinase JAK1 inhibitor] (phase-IV)
JAK1	polycythemia vera	40	ruxolitinib phosphate [Tyrosine-protein kinase JAK1 inhibitor] (phase-IV)
JAK1	primary myelofibrosis	40	ruxolitinib phosphate [Tyrosine-protein kinase JAK1 inhibitor] (phase-IV)
IL6R	immune system disease	41	sarilumab [Interleukin-6 receptor alpha subunit antagonist] (phase-IV), satralizumab [IL6Ralpha/GP130 antagonist] (phase-IV), tocilizumab [Interleukin-6 receptor alpha subunit inhibitor] (phase-IV)
IL6R	rheumatoid arthritis	42	sarilumab [Interleukin-6 receptor alpha subunit antagonist] (phase-IV), tocilizumab [Interleukin-6 receptor alpha subunit inhibitor] (phase-IV)
IL6R	neuromyelitis optica	43	satralizumab [IL6Ralpha/GP130 antagonist] (phase-IV)
IL6	Castleman disease	44	siltuximab [Interleukin-6 inhibitor] (phase-IV)
IL6	Giant Lymph Node Hyperplasia	44	siltuximab [Interleukin-6 inhibitor] (phase-IV)
IL6	immune system disease	44	siltuximab [Interleukin-6 inhibitor] (phase-IV)
DPP4	hyperlipidemia	45	sitagliptin phosphate [Dipeptidyl peptidase IV inhibitor] (phase-IV)
DPP4	myocardial infarction	45	sitagliptin phosphate [Dipeptidyl peptidase IV inhibitor] (phase-IV)
DPP4	stroke	45	sitagliptin phosphate [Dipeptidyl peptidase IV inhibitor] (phase-IV)
IL6R	juvenile idiopathic arthritis	46	tocilizumab [Interleukin-6 receptor alpha subunit inhibitor] (phase-IV)
IL6R	systemic scleroderma	46	tocilizumab [Interleukin-6 receptor alpha subunit inhibitor] (phase-IV)
IL6R	temporal arteritis	46	tocilizumab [Interleukin-6 receptor alpha subunit inhibitor] (phase-IV)
JAK2	psoriatic arthritis	47	tofacitinib citrate [Janus Kinase (JAK) inhibitor] (phase-IV)
JAK1	psoriatic arthritis	47	tofacitinib citrate [Janus Kinase (JAK) inhibitor] (phase-IV)